HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes
暂无分享,去创建一个
H. Mackay | Naveena Singh | T. Bosse | L. Mileshkin | A. Leary | V. Smit | N. Horeweg | E. Crosbie | C. Creutzberg | M. Powell | L. Vermij | A. León-Castillo | T. Rutten | N. Singh | A. Léon-Castillo
[1] H. Putter,et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Secord,et al. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis , 2020, Clinical Cancer Research.
[3] P. Gariglio,et al. Mutant p53 gain of function induces HER2 over-expression in cancer cells , 2018, BMC Cancer.
[4] John M S Bartlett,et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.
[5] A. Talhouk,et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] A. Secord,et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Putter,et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial , 2018, The Lancet. Oncology.
[8] K. Kalland,et al. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions , 2017, British Journal of Cancer.
[9] C. Sessa,et al. Appendix 5: Endometrial cancer: eUpdate published online 8 June 2017 (www.esmo.org/Guidelines/Gynaecological-Cancers). , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] A. Talhouk,et al. Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer , 2017, Cancer.
[11] S. Kakar,et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Kakar,et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. , 2016, American journal of clinical pathology.
[13] D. Lambrechts,et al. Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma. , 2016, Anticancer research.
[14] H. Putter,et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts , 2016, Clinical Cancer Research.
[15] E. Ratner,et al. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas , 2015, British Journal of Cancer.
[16] B. Rueda,et al. The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. , 2015, The oncologist.
[17] A. Talhouk,et al. A clinically applicable molecular-based classification for endometrial cancers , 2015, British Journal of Cancer.
[18] C. Coutant,et al. Just how accurate are the major risk stratification systems for early-stage endometrial cancer? , 2015, British Journal of Cancer.
[19] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[20] Carsten Denkert,et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] N. Marchenko,et al. A gain-of-function mutant p53–HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress , 2014, Cell Death and Disease.
[22] A. Santin,et al. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. , 2014, Archives of pathology & laboratory medicine.
[23] Deanna M. Church,et al. ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..
[24] P. Hui,et al. Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma , 2013, Genes, chromosomes & cancer.
[25] P. Hui,et al. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice , 2013, Modern Pathology.
[26] C Blake Gilks,et al. Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma , 2013, The American journal of surgical pathology.
[27] Steven J. M. Jones,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[28] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[29] Manfred Dietel,et al. HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing , 2010, Virchows Archiv.
[30] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[31] J. Berek,et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. , 2010, Gynecologic oncology.
[32] A. Mariani,et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer , 2008, British Journal of Cancer.
[33] S. Henikoff,et al. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.
[34] A. Jimeno,et al. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] M. J. van de Vijver,et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study , 2008, Histopathology.
[36] G. Mills,et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.
[37] David Cameron,et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.
[38] C. Morrison,et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] B. Iacopetta,et al. PIK3CA mutations in breast cancer are associated with poor outcome , 2006, Breast Cancer Research and Treatment.
[40] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[41] Hanina Hibshoosh,et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.
[42] C. Sotiriou,et al. HER-2/neu Gene and protein in breast cancer , 2004 .
[43] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[44] S. Bull,et al. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] K. Bloom,et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.
[46] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[47] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.